GSK Redo Doesn't Cure Generics' 'Skinny Label' Uncertainty
While the Federal Circuit may have walked back part of an induced infringement ruling that left the generic-drug industry warning a fundamental law had been gutted, attorneys say the court's revised...To view the full article, register now.
Already a subscriber? Click here to view full article